Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus – Nasdaq
Bloomberg |
Kymriah, First CAR–T Therapy Approved: 4 Pharma Stocks in Focus
Nasdaq Kymriah, formerly CTL019, is the first chimeric antigen receptor T cell (CAR-T) therapy approved. A novel immunocellular therapy and one-time treatment, Kymriah uses patient's T cells to fight cancer. While the long-term impact of the treatment is yet … FDA Vows Modernization to Keep Up With Biotech Advances |
